Celldex Therapeutics Inc. [CLDX] stock is trading at $41.99, down -5.77%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLDX shares have gain 15.55% over the last week, with a monthly amount glided 11.41%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Celldex Therapeutics Inc. [NASDAQ: CLDX] stock has seen the most recent analyst activity on June 18, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $58. Previously, Wolfe Research started tracking the stock with Outperform rating on June 11, 2024, and set its price target to $51. On December 20, 2023, TD Cowen initiated with a Outperform rating. Wells Fargo upgraded its rating to a Equal Weight but stick to its price target of $27 on November 10, 2023. Wells Fargo initiated its recommendation with a Underweight and recommended $21 as its price target on August 22, 2023. Jefferies started tracking with a Buy rating for this stock on September 17, 2021, and assigned it a price target of $66. In a note dated September 10, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $68 on this stock.
Celldex Therapeutics Inc. [CLDX] stock has fluctuated between $22.11 and $53.18 over the past year. Currently, Wall Street analysts expect the stock to reach $49.33 within the next 12 months. Celldex Therapeutics Inc. [NASDAQ: CLDX] shares were valued at $41.99 at the most recent close of the market. An investor can expect a potential return of 17.48% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Celldex Therapeutics Inc. [NASDAQ:CLDX] reported sales of 6.07M for the trailing twelve months, which represents a drop of -83.87%. Gross Profit Margin for this corporation currently stands at 0.5% with Operating Profit Margin at -24.73%, Pretax Profit Margin comes in at -23.86%, and Net Profit Margin reading is -23.86%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.32 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.83 points at the first support level, and at 39.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.89, and for the 2nd resistance point, it is at 45.78.
Ratios To Look Out For
For context, Celldex Therapeutics Inc.’s Current Ratio is 31.77. In addition, the Quick Ratio stands at 31.77 and the Cash Ratio stands at 4.38. Considering the valuation of this stock, the price to sales ratio is 455.94, the price to book ratio is 3.30.
Transactions by insiders
Recent insider trading involved Crowley Elizabeth, SR. VP & CPDO, that happened on Jun 14 ’24 when 30000.0 shares were sold. SVP AND CFO, Martin Samuel Bates completed a deal on Jun 14 ’24 to sell 17172.0 shares. Meanwhile, SVP, CHIEF MEDICAL OFFICER Young Diane C. sold 45000.0 shares on Jun 07 ’24.
